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Abstract
The efficacy of ACTH, particularly in high doses, for rapid and complete elimination of infantile
spasms (IS) has been demonstrated in prospective controlled studies. However, the mechanisms
for this efficacy remain unknown. ACTH promotes the release of adrenal steroids
(glucocorticoids), and most ACTH effects on the central nervous system have been attributed to
activation of glucocorticoid receptors. The manner in which activation of these receptors improves
IS and the basis for the enhanced therapeutic effects of ACTH — compared with steroids — for
this disorder are the focus of this chapter. First, a possible “common excitatory pathway,” which is
consistent with the many etiologies of IS and explains the confinement of this disorder to infancy,
is proposed. This notion is based on the fact that all of the entities provoking IS activate the native
“stress system” of the brain. This involves increased synthesis and release of the stress-activated
neuropeptide, corticotropin-releasing hormone (CRH), in limbic, seizure-prone brain regions.
CRH causes severe seizures in developing experimental animals, as well as limbic neuronal injury.
Steroids, given as therapy or secreted from the adrenal gland upon treatment with ACTH, decrease
the production and release of CRH in certain brain regions. Second, the hypothesis that ACTH
directly influences limbic neurons via the recently characterized melanocortin receptors is
considered, focusing on the effects of ACTH on the expression of CRH. Experimental data
showing that ACTH potently reduces CRH expression in amygdala neurons is presented. This
downregulation was not abolished by experimental elimination of steroids or by blocking their
receptors and was reproduced by a centrally administered ACTH fragment that does not promote
steroid release. Importantly, selective blocking of melanocortin receptors prevented ACTH-
induced downregulation of CRH expression, providing direct evidence for the involvement of
these receptors in the mechanisms by which ACTH exerts this effect. Thus, ACTH may reduce
neuronal excitability in IS by two mechanisms of action: (1) by inducing steroid release and (2) by
a direct, steroid-independent action on melanocortin receptors. These combined effects may
explain the robust established clinical effects of ACTH in the therapy of IS.
I. How Do the Many Etiologies of Infantile Spasms (IS) Lead to Excitability
and Seizures? The Scope of the Problem
IS is an age-specific disorder of brain excitability, with diverse genetic, teratogenic,
perinatal, and postnatally acquired etiological factors. Two key elements characteristic of
this entity are (1) the remarkable number and variability of the predisposing factors and (2)
the fact that regardless of the time of onset of the underlying etiology (i.e., conception,
intrauterine, prenatal, perinatal, or postnatal), IS commence at a distinct developmental age
(typically the third to seventh postnatal month). These facts have suggested that (a) there
must be a “final common pathway” for the etiologies, leading to IS, and (b) this final
common pathway must be operative only during the state of brain maturation that occurs
during infancy.
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Mechanistic theories for the development of IS have included those invoking abnormal
immune function, brain stem dysfunction (Hrachovy and Frost, 1989), developmental arrest
(Riikonen, 1983), and cortical microdysplasia (Vinters et al., 1992; DallaBernadina and
Dulac, 1994). The latter has gained in popularity with the advent of magnetic resonance
imaging. However, foci of microdysgenesis have been described in autopsied brains of
normal individuals (Lyon and Gastaut, 1985), casting doubt on the etiological role of these
in IS. In addition, the majority of infants with symptomatic IS have etiologies, such as those
of metabolic, chromosomal, or infectious nature, that do not involve cortical dysplasias or
other structural anomalies.
Any theory for the pathogenesis of IS has to account for the unique features of this disorder.
For example, how can a single entity have so many etiologies? Why do IS arise only in
infancy, even when a known insult had occurred prenatally, and why do they disappear?
Why are IS associated with lasting cognitive dysfunction, and why do these seizures —
unlike most others — respond to ACTH [in 86–88% of cases (Baram et al., 1996)]. ACTH
may accelerate central nervous system (CNS) myelination and dendritic formation, and thus
may shorten a hypothetical period of vulnerability to IS (Riikonen, 1983). ACTH may also
act as a direct anticonvulsant via GABAergic or other mechanisms (Holmes, 1987).
However, the hormonal actions of ACTH (as opposed to other potential effects) have been
shown to be necessary for efficacy, as analogs of ACTH without hormonal effects do not
eliminate IS (Pentella et al., 1982; Willing and Lagenstein, 1982). Furthermore, the rapid
(median response time of 2 days), all-or-none, and often permanent effects of ACTH on IS
are not consistent with conventional anticonvulsant properties (Hrachovy and Frost, 1989;
Baram, 1993; Baram et al., 1996, 1999).
II. Can the Seizure-Selective, Striking Efficacy of ACTH for IS Provide
Insight into the Mechanisms of This Disorder?
A. The Known Hormonal Role of ACTH Is to Induce High Plasma and Brain Steroid Levels
The established hormonal role of ACTH in human physiology is to function in the
neuroendocrine cascade of the responses to all stressful stimuli, including insults to the
brain. Native ACTH is synthesized in the pituitary and functions to stimulate the adrenal
cortex to release steroids into the bloodstream as part of the neuroendocrine stress response
(Fig. 1). ACTH, whether released from the pituitary or given as therapy, functions via
promoting the release of glucocorticoids (steroids, primarily Cortisol in the human and
corticosterone in the rat) from the adrenal gland. These hormones have a multitude of effects
throughout the body. Importantly, steroids cross the blood–brain barrier readily and bind to
receptors that are widely expressed throughout the brain. Activation of glucocorticoid
receptors has little direct anticonvulsant effects (Karst et al., 1994). However,
glucocorticoids modulate the expression and release of a number of neurotransmitters and
neuromodulators, including the proconvulsant neuropeptide corticotropin-releasing hormone
(CRH).
B. The Many Etiologies of IS Activate the Corticotropin-Releasing Hormone (CRH) –ACTH–
Steroid Cascade: Human and Animal Data
IS, at least the symptomatic cases, occur in the context of an insulted and stressed
developing brain (Baram, 1993). The many etiologies of IS all lead to activation of the stress
response, including the stress neurohormone CRH. CRH has been shown, in infant animal
models, to cause severe seizures and death of neurons in areas involved with learning and
memory (Baram et al., 1992a; Brunson et al., 2001a). These effects of CRH are largely
restricted to the infancy period because the receptors for CRH, which mediate its actions on
neurons, are most abundant during this developmental period (Avishai-Eliner et al., 1996;
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Baram and Hatalski, 1998). The mechanisms by which CRH increases excitability of limbic
neurons have been examined in vitro (e.g., Aldenhoff et al., 1983; Hollrigel et al., 1998) and
involve a suppression of afterhyperpolarization and a potentiation of glutamatergic
neurotransmission. Thus, the possibility that IS result from “excessive” levels of CRH in
limbic synapses, which are a result of activation of the production and secretion of CRH as
part of the CNS stress response to the etiologies of IS, has been suggested (Baram, 1993;
Baram and Hatalski, 1998; Baram et al., 1999).
Data from human infants with IS support a disruption of the CRH–ACTH stress cascade in
the brains of these infants. High brain CRH levels are expected to reduce cerebrospinal fluid
(CSF) levels of ACTH and of steroids [because chronic activation of CRH receptors leads to
their desensitization (Hauger et al., 1993) and decreased ACTH release]. Indeed, several
groups have independently reported reduced ACTH levels in IS patients compared with age-
matched controls (Nalin et al., 1985; Baram et al., 1992b; 1995; Heiskala, 1997). Thus,
these data are consistent with enhanced levels of endogenous CRH in brains of youngsters
with IS. Based on animal data described later, increased CRH at limbic synapses should
promote increased excitability, potentially leading to the chronically abnormal neuronal
activity (hypsarrhythmia) and spasms characteristic of IS.
C. Excess CRH Provokes Limbic Seizures Involving the Amygdala and Hippocampus
In an immature rat, particularly during the stage of brain development that is comparable to
that of human infants, administration of minute amounts of CRH directly into the CSF
causes prolonged and severe seizures (Baram and Schultz, 1991; Baram et al., 1992a; Baram
and Hatalski, 1998). These seizures involve activation of CRH receptors in the amygdala
and hippocampus. Therefore, it is reasonable to assume that increased levels of endogenous
CRH in the amygdala and hippocampus would also increase excitability in the amygdala–
hippocampal limbic circuit. Interestingly, CRH is highly expressed in both immature and
adult central nucleus of the amygdala (Gray and Bingaman, 1996; Hatalski et al., 1998). A
robust expression of CRH in hippocampal neurons has been demonstrated as well (Yan et
al., 1998), although levels of CRH in mature hippocampus are rather low (Swanson et al.,
1983). In addition, recurrent stress has been shown to increase CRH levels in the amygdala
of the infant rat (Hatalski et al., 1998), and some stresses also increase CRH expression in
the immature hippocampus (Hatalski et al., 2000). Therefore, the following scenario may be
considered: The many etiologies of IS share the common denominator of being “stressful” to
the immature brain in the sense of activating the intrinsic stress response. While stress does
not increase CRH synthesis in the neonate (Yi and Baram, 1994), increased CRH levels in
the amygdala, and potentially in the hippocampus, does occur in the infant. This would lead
to excess activation of CRH receptors, abundant during infancy in amygdala and
hippocampus (see earlier discussion), and to hyperexcitability and seizures. Drastic
reduction in the abundance of CRH receptors, occurring with maturation, would be
responsible for the reduction in this peptide-mediated hyperexcitability later in life (Baram
and Hatalski, 1998).
D. ACTH, Acting via Steroids, Modulates Excitability via Altering CRH Expression
Earlier studies have focused on the hormonal action of ACTH, specifically of its induction
of steroid release, as the key mechanism of its efficacy for IS. This view was supported by
several facts. First, steroids by themselves are effective in a significant portion of infants
with IS. In addition, ACTH fragments that did not release steroids were not effective for IS.
(It is now known, however, that these fragments also do not activate ACTH/melanocortin
receptors in the brain, see later.) While the full spectrum of the mechanisms of action of
steroids in ameliorating IS is unknown (see, e.g., Karst et al., 1994; Pavlides et al., 1995),
these hormones reduce CRH expression in some brain regions, notably in the brain stem
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(Imaki et al., 1991), a region suspected to be involved in IS (Hrachovy and Frost, 1989).
However, steroids do not reduce CRH levels in limbic regions such as the amygdala and
hippocampus.
III. Direct Actions of ACTH May Modulate Excitability Independent of
Steroids by Downregulating CRH Expression in Limbic Regions
A. Distribution and Roles of Native, Endogenous ACTH
Neurons containing ACTH have been localized to the CNS, particularly the hypothalamus,
and ACTH-immunoreactive cell bodies or fibers have also been described in the amygdala,
cerebral cortex, brain stem, and cerebellum (Pilcher and Joseph, 1984). In contrast to
pituitary ACTH, the functions of CNS–ACTH have not been well defined. Evidence from
both human and animal studies has suggested that CNS–ACTH may function as a
neurotransmitter or neuromodulator (Pranzatelli, 1994; de Wied, 1977). Indeed, central
physiological roles for ACTH, including modulation of learning and memory processes and
facilitation of arousal states, have been suggested, but the mechanisms for these actions of
ACTH have remained unclear (Pranzatelli, 1994; de Wied, 1977). Characterization of the
melanocortin receptor family, consisting of several members possessing binding affinity for
ACTH (Mountjoy et al., 1992; Adan and Gispen, 1997), has yielded insight regarding the
likely sites and mechanisms of ACTH effects. However, the downstream effects of
activation of these receptors and the specific molecular changes that can lead to the clinical
effects of ACTH on CNS function have not been elucidated.
As mentioned earlier, pituitary ACTH synthesis and secretion are regulated by CRH, and
both hormones participate in the neuroendocrine response to stress (Fig. 1). Conversely,
ACTH reduces CRH gene expression in the hypothalamus as part of the neuroendocrine
feedback loop of the stress response (Sawchenko and Arias, 1995). ACTH and CRH are
found in close proximity in excitable, seizure-prone brain regions such as the amygdala, and
complex interactions between ACTH- and CRH-expressing neuronal systems have been
suggested (Wu et al., 1997; Hauger et al., 1993; Joseph et al., 1985). For example, ACTH-
immunoreactive fibers have been demonstrated in the central nucleus of the amygdala, a
major limbic locus of CRH-expressing neurons. As mentioned earlier, CRH production in
the central nucleus is activated when diverse stressors or brain insults induce the
neuroendocrine stress cascade. In view of these facts, could suppression of CRH expression
in the central nucleus of the amygdala and the resulting reduced excitability (Baram et al.,
1992a) account for some of the actions of ACTH on IS?
B. Experimental Evidence for Direct Reduction of CRH Expression in the Central Nucleus
of the Amygdala by ACTH
ACTH, in the form typically used for therapy of IS in the United States (ACTHARGEL,
Rhone-Poulenc Rorer, Collegeville, PA), was administered into the peritoneal cavity (ip) of
infant rats at a high dose (80 IU/kg) because of the limited blood–brain barrier penetration of
the peptide (Nicholson et al., 1978; Mezey et al., 1878). ACTH4–10, an analog that binds
melanocortin receptors but does not induce steroid secretion from the adrenal, was also
tested and infused directly into the cerebral ventricles (Brunson et al., 2001b). Steroid
receptors were blocked using RU 38486 (Roussel UCLAF, Romainville, France), whereas
melanocortin receptors were blocked using SHU9119 (courtesy Dr. K. Yagaloff, Roche,
New Jersey).
The effects of ACTH in the presence and absence of endogenous steroids, and with blockade
of steroid or ACTH/melanocortin receptors, were examined in infant rats. CRH expression
in the central nucleus of the amygdala was determined using semiquantitative in situ
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hybridization histochemistry (ISH; Eghbal-Ahmadi et al., 1999; Brunson et al., 2001).
Analysis of the CRH–mRNA ISH signal was performed as described in these publications,
including unbiased sampling of sections, and performance of all analyses without
knowledge of treatment group (“blindly”). C14 standards were used to ascertain that
analyzed signals fell in the linear range, and values were expressed as relative optical
density units. Differences among groups were determined using a one-way ANOVA or
student’s t test, as appropriate (Prism GraphPad, San Diego, CA), and significance levels
were set at p < 0.05. Further analysis used Tukey’s multiple comparison posthoc tests to
determine the source of the detected significance in the ANOVAs.
Administration of ACTH downregulated CRH expression in the central nucleus by 35%,
considered highly significant physiologically (for review, see Hatalski et al., 1998).
Glucocorticoid receptor activation was not required for the ACTH-induced downregulation
of CRH expression because this downregulation was also observed in the absence of
endogenous steroids: in adrenalectomized rats — as in intact littermates — ACTH resulted
in a significant (33%) suppression of CRH expression. It should be noted that adrenalectomy
— eliminating steroids and the consequent negative feedback on ACTH secretion —
resulted in high levels of intrinsic, endogenous ACTH. These ACTH levels, by themselves,
were sufficient to significantly downregulate CRH expression (34% reduction from sham-
operated controls).
The effect of ACTH on CRH expression in amygdala was central: Similar to systemically
administered ACTH, the analog ACTH4–10 infused into the CSF resulted in a significant
downregulation of CRH expression (45% reduction from vehicle-infused control levels).
The dose of the ACTH4–10 analog was relatively small and was therefore unlikely to reach
the adrenal when given centrally. In addition, this ACTH analog does not stimulate
corticosterone secretion from the adrenal and did not raise plasma steroid levels in the
experiments described here. These data suggest that ACTH4–10 (and ACTH) reduced CRH
expression in amygdala via a central rather than a steroid-mediated peripheral mechanism.
A specific blockade of melanocortin receptors or of glucocorticoid receptor occupancy
demonstrated that occupancy and activation of the former were required for the action of
ACTH on amygdala CRH: SHU9119, a blocker of melanocortin receptors, blocked ACTH-
induced reduction of CRH expression. In contrast, when RU 38486, a glucocorticoid
receptor blocker, was given to intact animals together with ACTH, it failed to block the
effects of ACTH administration on CRH expression in amygdala (a 63% reduction from ip
injected controls). These data indicate that activation of melanocortin receptors, but not of
glucocorticoid receptors, is required for the actions of ACTH on CRH expression in the
central nucleus of the amygdala.
IV. Implications of Steroid-Independent Effects of ACTH for the Therapy of
IS
The studies described here demonstrate direct actions of systemically or centrally
administered ACTH on limbic neurons that are independent of adrenal steroids. ACTH-
induced reduction of CRH expression in the amygdala may provide a mechanism for the
efficacy of ACTH in IS and, potentially, in other human disorders. Importantly, these effects
of ACTH involve activation of specific melanocortin receptors, which may provide new and
important therapeutic targets.
ACTH, particularly in high doses, has been shown to provide efficacy for IS (86–88%),
which is greater than that of steroids. Indeed, controlled prospective and blinded studies
demonstrated a clear superiority of high doses of ACTH over steroids (Baram et al., 1996,
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but see Hrachovy et al., 1983). These clinical data raise several issues. First, if ACTH acts
via steroids, then maximal doses of both agents should have similar effects. Second, once
doses of ACTH that suffice to maximally release endogenous steroids are used, then higher
doses should not have additional benefits. The enhanced potency of ACTH compared with
steroids and the superiority of extremely high doses of ACTH compared with lower ones are
consistent with direct, steroid-independent actions of ACTH within the CNS. In addition, the
poor penetration of systemically given ACTH through the blood–brain barrier (Nicholson et
al., 1978; Mezey et al., 1978) may underlie the requirement for large systemic doses.
The studies described here support the notion of direct CNS actions of ACTH. Using doses
analogous to those used clinically, systemic ACTH influenced the expression of CRH in
specific brain regions regardless of the presence or absence of adrenal steroids. These effects
were generated by ACTH given both systemically or directly into the cerebral ventricles and
persisted when glucocorticoid receptors were blocked, but not when a subtype of ACTH
receptors (melanocortin receptors) was antagonized, showing that activation of these latter
receptors was required and sufficient for these actions of ACTH.
Melanocortin receptors, a family of transmembrane G-protein-coupled receptors, have been
demonstrated in regions subserving ACTH-mediated functions (e.g., substantia nigra for
grooming and amygdala for learning and memory). In addition, activation of central
melanocortin receptors plays a role in appetitive and grooming behavior (Adan and Gispen,
1997; Fisher et al., 1999). Data reviewed in this chapter demonstrate that ACTH may
activate melanocortin receptor type 4 and are consistent with a scenario in which ACTH,
released from fiber terminals in the central nucleus of the amygdala, acts locally on
melanocortin receptors located on CRH-expressing neurons. ACTH, given in clinical
settings, should mimic these effects.
Interestingly, the (4–10) fragment of ACTH that does not release adrenal steroids also led to
the depression of CRH gene expression. Earlier clinical studies have shown that shorter
fragments (4–9) of ACTH, which failed to release adrenal steroids, were not efficacious for
infantile spasms (Willig and Lagenstein, 1982; Pentella et al., 1982). Currently available
information explains the apparent discrepancy: new information about the binding of ACTH
fragments to melanocortin receptors shows that while the 4–10 fragment used here activates
these receptors, the 4–9 fragment does not (Adan and Gispen, 1997; Gantz et al., 1993).
Again, these data are consistent with activation of melanocortin receptors as the mechanism
for the observed effects of ACTH on amygdala neurons.
In summary, data discussed here provide two potential mechanisms for the efficacy of
ACTH for developmental seizure disorders and specifically for IS. The first is the
“conventional” activation of steroid release and the second involves the direct modulation of
amygdala neurons leading to decreased production of the proconvulsant peptide CRH.
Importantly, data reviewed here highlight components of the ACTH–CRH system as
potential targets for the development of new therapeutic agents for IS.
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Fig. 1.
Neuroendocrine (A) and limbic (B) stress-activated corticotropin-releasing hormone (CRH)
loops. (A) Stress-conveying signals rapidly activate immediate early genes in CRH
expressing neurons of the central nucleus of the amygdala (ACe). Rapid CRH release in the
ACe activates CRH expression in the hypothalamic paraventricular nucleus (PVN) to secrete
CRH into the hypothalamo-pituitary portal system, inducing ACTH and glucocorticoid
secretion from the pituitary and adrenal, respectively. Glucocorticoids exert a negative
feedback on the PVN (directly and via the hippocampus), yet activate CRH gene expression
in the amygdala, potentially promoting further CRH release in this region. (B) CRH-
expressing GABAergic interneurons (small round cells) in the principal cell layers of the
hippocampal CA1, CA3, and the dentate gyrus (DG) are positioned to control excitability of
the pyramidal and granule cells, respectively. These neurons may be influenced by the
stress-evoked release of CRH from the ACe via connections in the entorhinal cortex. Dark
and light arrows denote established or putative potentiating and inhibitory actions,
respectively. Arrows do not imply monosynaptic connections.
Brunson et al. Page 10
Int Rev Neurobiol. Author manuscript; available in PMC 2011 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
